Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on September 24, 2007

Circulation. 2007
Published online before print September 24, 2007, doi: 10.1161/CIRCULATIONAHA.107.698662
A more recent version of this article appeared on October 16, 2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
116/16/1776    most recent
CIRCULATIONAHA.107.698662v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Okumura, S.
Right arrow Articles by Ishikawa, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Okumura, S.
Right arrow Articles by Ishikawa, Y.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ADENOSINE 5'-PHOSPHATE
Medline Plus Health Information
*Heart Failure
Related Collections
Right arrow Apoptosis
Right arrow Cell signalling/signal transduction
Right arrow Genetically altered mice
Right arrow Heart failure - basic studies
Right arrow Receptor pharmacology

Submitted on February 27, 2007
Accepted on August 13, 2007

Disruption of Type 5 Adenylyl Cyclase Enhances Desensitization of Cyclic Adenosine Monophosphate Signal and Increases Akt Signal With Chronic Catecholamine Stress

Satoshi Okumura MD, PhD, Dorothy E. Vatner MD, Reiko Kurotani PhD, Yunzhe Bai MD, Shumin Gao MD, Zengrong Yuan MD, PhD, Kousaku Iwatsubo MD, PhD, Coskun Ulucan MD, PhD, Jun-ichi Kawabe MD, PhD, Kaushik Ghosh PhD, Stephen F. Vatner MD, and Yoshihiro Ishikawa MD, PhD*

From the Cardiovascular Research Institute, Department of Cell Biology and Molecular Medicine and Medicine (Cardiology), University of Medicine and Dentistry of New Jersey, New Jersey Medical School (D.E.V., S.G., Z.Y., K.I., C.U., J.K., S.F.V., Y.I.), Newark; Cardiovascular Research Institute, Yokohama City University Graduate School of Medicine (S.O., R.K., Y.B., C.U., Y.I.), Yokohama, Japan; and Department of Mathematical Sciences, New Jersey Institute of Technology (K.G.), Newark.

* To whom correspondence should be addressed. E-mail: ishikayo{at}umdnj.edu.

Background—Desensitization of the cyclic adenosine monophosphate signal protects cardiac myocytes against catecholamine stress, thus preventing the development of apoptosis. Molecular mechanisms of desensitization have been well studied at the level of adrenergic receptors but less so at the level of the effector enzyme, adenylyl cyclase (AC).

Methods and Results—When the effects of long-term (1 to 2 weeks) isoproterenol infusion were compared between type 5 AC-null mice (AC5KO) and wild-type controls, we found that the subsequent responses of left ventricular ejection fraction to sudden intravenous isoproterenol challenge were reduced in AC5KO compared with wild-type mice (ie, physiological desensitization was more effective in AC5KO), consistent with enhanced downregulation of AC catalytic activity in AC5KO. One mechanism for the less effective desensitization in wild-type mice was paradoxical upregulation of type 5 AC protein expression. The number of apoptotic myocytes was similar at baseline but was significantly less in AC5KO after infusion. This was accompanied by a 4-fold greater increase in Bcl-2 and a 3-fold greater increase in phospho-Akt in AC5KO. The latter is most likely mediated by increased membrane localization of phosphoinositide-dependent protein kinase 1, which is known to be inhibited by the cyclic adenosine monophosphate signal.

Conclusions—The absence of type 5 AC results in more effective desensitization after long-term catecholamine stress and protects against the development of myocyte apoptosis and deterioration of cardiac function, potentially elucidating a novel approach to the therapy of heart failure.


Key words: catecholamines • heart failure • apoptosis • signal transduction




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C.-L. Hu, R. Chandra, H. Ge, J. Pain, L. Yan, G. Babu, C. Depre, K. Iwatsubo, Y. Ishikawa, J. Sadoshima, et al.
Adenylyl cyclase type 5 protein expression during cardiac development and stress
Am J Physiol Heart Circ Physiol, November 1, 2009; 297(5): H1776 - H1782.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. S. Kapiloff, L. A. Piggott, R. Sadana, J. Li, L. A. Heredia, E. Henson, R. Efendiev, and C. W. Dessauer
An Adenylyl Cyclase-mAKAP{beta} Signaling Complex Regulates cAMP Levels in Cardiac Myocytes
J. Biol. Chem., August 28, 2009; 284(35): 23540 - 23546.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
V. Rajagopalan, I. H. Zucker, J. A. Jones, M. Carlson, and Y. J. Ma
Cardiac ErbB-1/ErbB-2 mutant expression in young adult mice leads to cardiac dysfunction
Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H543 - H554.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
S. Okumura, T. Tsunematsu, Y. Bai, Q. Jiao, S. Ono, S. Suzuki, R. Kurotani, M. Sato, S. Minamisawa, S. Umemura, et al.
Type 5 adenylyl cyclase plays a major role in stabilizing heart rate in response to microgravity induced by parabolic flight
J Appl Physiol, July 1, 2008; 105(1): 173 - 179.
[Abstract] [Full Text] [PDF]